MedTrace Logo

Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

NCT02380222 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2017-01-10

No results posted yet for this study

Summary

The purpose of this study is to explore the key symptoms of individuals with systemic mastocytosis. Interviews of enrolled individuals will be conducted to learn about the disease symptoms and condition. The interview will last approximately 60 minutes and will be conducted by a trained interviewer, be audio-recorded (with patient consent), and all information provided by the patient will be treated confidentially and made anonymous so that it is non-identifiable. The interview may be conducted face-to-face, over the phone, or virtually via Skype, a free video conferencing program, depending upon the patient's geographic location. Patients will be compensated for their participating time.

This is not a medication-related study, and no medication will be distributed or tested during this study. Participation in this study will not affect any treatment or assistance that a patient currently receives or may receive in the future.

Conditions

  • Aggressive Systemic Mastocytosis (ASM)
  • SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD)
  • Mast Cell Leukemia (MCL)
  • Smoldering Systemic Mastocytosis (SSM)
  • Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited

Interventions

OTHER

Interview

Single interview lasting approximately one hour

Sponsors & Collaborators

  • Blueprint Medicines Corporation

    collaborator INDUSTRY

  • Adelphi Values LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02380222 on ClinicalTrials.gov